Artrya (ASX:AYA) Signs First U.S. Hospital Partnership – The Market Herald

0

Subscribe

Be the first with news that moves the market

  • AI-Based Diagnostic Imaging Company Artrya (AYA) Signs First U.S. Hospital Clinical Partnership with Huntsville Heart Center in Alabama
  • The study will be conducted by Heart Center Research, a division of Huntsville Heart Center, to determine the effectiveness of Artrya’s technology
  • The study will use Artrya’s Salix Coronary Anatomy technology to report a unique combination of coronary heart disease biomarkers, including high-risk plaque components
  • Artrya also announced that the CEO from 2006 to 2012 of the American College of Cardiology in the United States, Dr. John Lewin, has joined its clinical advisory board.
  • Artrya ends the day in the gray with shares trading at 70 cents

AI-based diagnostic imaging company Artrya (AYA) has signed its first US hospital clinical partnership with Huntsville Heart Center in Alabama.

The study will be conducted by Heart Center Research, a division of Huntsville Heart Center, to determine the effectiveness of Artrya’s technology.

The study will use Artrya’s Salix Coronary Anatomy technology to report a unique combination of coronary heart disease biomarkers, including high-risk plaque components.

“This is the company’s first clinical partnership in the United States, and we are thrilled that such a reputable cardiac center has joined our mission to create better detection of the world’s number one killer, heart disease,” Jory Tremblay and Ted Schwab, co-CEO of Artrya USA, commented.

“This clinical trial is expected to be completed by October of this year and provide validation of the technology and pave the way for its commercial use in the United States.”

Artrya also announced that the 2006-2012 CEO of the American College of Cardiology in the United States, Dr. John Lewin, has joined its Clinical Advisory Board.

Artrya ended the day in the gray with shares trading at 70 cents.

Share.

Comments are closed.